Aliskiren, Obat Antihipertensi Baru dengan Mekanisme Penghambat Renin
Keywords:
Aliskiren, hypertension, reninAbstract
Hypertension is a chronic disease with a prevalence reaching 1 billion people around the world. Hypertension is the major treatable risk factor for cardiovascular disease, which remains the leading cause of death in the industrialized world. Despite the risks associated with the condition, the majority of patients with hypertension across the world do not have their blood pressure (BP) controlled to recommended target levels. RAAS is a main target, although, in total inhibition of RAAS can not be obtained with ACEI and ARB class of drugs because of the feedback mechanism. As a solution, we could inhibit the early stages of the mechanism, that is renin. Previous studies have indicated that the renin inhibitor class of drugs effective as antihypertensive and well tolerated, both as monotherapy and in combination with other drugs. Based on researched to aliskiren and the success of antihypertensive drug class of ACEI and ARB in reducing morbidity and mortality in patients with hypertension, it is rational if the expected drug classes like renin inhibitor aliskiren would provide the same benefits. Whether the benefits are equal, larger or even smaller than another RAAS inhibitor, we needed long research to find supporting data.
References
Muller, D.N.; & Luft, F.C. 2006,Direct Renin Inhibition with Aliskiren in Hypertension and Target Organ Damage, Clin. J. Am. Soc. of Nephrology, 1: 221–228
Saseen, J.J.; & Carter, B.L.2005,Hypertension, inDiPiro J.T., Pharmacotherapy a Pathophysiologic Approach, McGraw-Hill
Nafrialdi. 2007,Hipertensi, in Farmakologi dan Terapi, Departemen Farmakologi dan Terapi, Fakultas Kedokteran UI, Jakarta
Sukandar, E.Y.; Andrajati, R.; Sigit, S.i.; Adyana, I.K.; Setiadi, A.P.; & Kusnandar. 2008, ISO Farmakoterapi, ISFI penerbitan. Jakarta
Gradman, A.H.; Schmieder, R.E.; Lins, R.L.; Nussberger, J.; Chianh, Y.; & Bedigian, M.P. 2005,Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-dependent Antihypertensive Efficacy and Placebo-like Tolerability in Hypertensive Patients, Circulation, 111, 1012-1018
Vaidyanathan, S.; Jermany, J.; Yeh, C.; Bizot, M.N.; Camisasca, R. 2006,Aliskiren, a Novel Orally Effective Renin Inhibitor, Exhibits Similar Pharmacokinetics and Pharmacodinamics in Japanesse and Caucasian Subjects, British J. Clin. Pharmacology, 62:6, 690-698
Jan Danser, A.H.; Charney, A.; Feldman, D.L.; Nussbenger, J.; Kisner, N.; & Hollenberg, N. 2008,The Renin Rise with Aliskiren, its Simply Stoichiometry, Hypertension, vol 51 e27-e28
Kushiro, T.; Itakura, H.; Yoshihisa, A.; Gatau, H.; Terdo, S.; & Keefe, D.L. 2006,Aliskiren, a Novel oral renin Inhibitor, Provides dose dependent Effecacy and Placebo like Tolerability in Japanese Patients with Hypertension, Hypertention Research, vol 29 no 997-1005
Oparil, S.; Yarrowa, S.; Patel, S.; Fang, S.; Yarrows, S.; Zhang, J.; & Zlatan, A. 2009,Efficacy and Safety of Combined use of Aliskiren and Valsartan in patient with Hypertention; Randomised double Blind Trial, The Lancet, vol 370 p 221-229
O’brien, E.; Barton, J.; Nussberger, J.; Mulcany, D.; Jensen, C.; Dicker, P.; & Stanton, A. 2007,Aliskiren Reduces Blood Pressure and Supresser Plasma Renin Activity in Combination with Thiazide Diuretics, an Angiotensin Converting Enzim Inhibitor or an Angiotensin Receptor Blocker, Hypertension,vol 49 p 276-284
Jordan, J.; Engeli, S.; Boye, S.W.; Le Broton, S.; & Keefe, D.L. 2007,Direct Renin Inhibition With Aliskiren in Obese Patient with Arterial Hypertension, Hypertension, vol 49 p 1047-1055
